Short‐term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1‐year placebo cohort analysis
Authors:
- 12 August 2010
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 27 (11) , 1271-1279
Abstract
Diabet. Med. 27, 1271–1279 (2010) Aims Randomized clinical trials have frequently shown improvement in diabetic sensorimotor polyneuropathy in placebo‐treated participants, counter to the prevailing concept that it deteriorates with time. We aimed to determine the variables associated with this paradoxical nerve function improvement.Methods Participants with diabetic sensorimotor polyneuropathy randomized to placebo in a multi‐centre, double‐blind study were evaluated for the primary outcome of 1‐year change in the summed sensory nerve conduction velocity of the bilateral sural and non‐dominant median nerves. Association with clinical and biochemical variables measured at 13 time points were examined.Results The 134 participants had mild to moderate diabetic sensorimotor polyneuropathy of 4.6 years’ duration and mean 1‐year improvement of 2.0 ± 8.0 m/s. Primary outcome measures were available for 122 participants (91%). In multivariate analyses, the change in HbA1c and serum triglycerides from baseline to 2 months demonstrated the strongest association, even independent of baseline and end‐of‐study levels. According to quintiles of change, we determined thresholds: participants with salutary improvement in HbA1c (exceeding a drop of –0.8%) or whose triglycerides did not increase (by 0.32 mmol/l or more) experienced significant improvement (2.9 m/s), while those with salutary levels of both these variables had an exaggerated improvement (5.1 m/s). In comparison, those with non‐salutary changes in both variables experienced a loss of –4.9 m/s (ANOVA P = 0.0014).Conclusions In mild to moderate diabetic sensorimotor polyneuropathy, short‐term improvements in glycaemic control and serum triglyceride levels have an independent, additive and durable effect on restoration of nerve function.Keywords
This publication has 28 references indexed in Scilit:
- DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural HistoryCurrent Diabetes Reports, 2010
- Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) StudyDiabetes Care, 2010
- Executive Summary: Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- Efficacy and Safety of Lacosamide in Diabetic Neuropathic PainThe Clinical Journal of Pain, 2009
- Elevated Triglycerides Correlate With Progression of Diabetic NeuropathyDiabetes, 2009
- Ranirestat for the Management of Diabetic Sensorimotor PolyneuropathyDiabetes Care, 2009
- Is patient satisfaction sensitive to changes in the quality of care? An exploitation of the Hawthorne effectJournal of Health Economics, 2008
- Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical TrialsDiabetes Care, 2007
- Established diabetic neuropathy seems irreversible despite improvements in metabolic and vascular risk markers—a retrospective case–control study in a hospital patient cohortDiabetic Medicine, 2006
- Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor PolyneuropathyDiabetes Care, 2006